ACCME data show commercial support for CME flat in 2007

Share this article:
Total commercial support of accredited CME scarcely budged in 2007, rising 1% to $1.2 billion, while the share of commercial support going to publishing and education companies declined 4.2% to $594 million, according to the ACCME's annual report.

Medical publishers and med ed agencies weren't the only providers to see support slide, data from the Accreditation Council for Continuing Medical Education (ACCME) show. Commercial support to government and military providers fell a whopping 94%, while support to hospitals plunged 18% and that going to medical schools fell 5%. Those gaining in commercial support: specialist societies and other non-profits, as well as insurance and managed care companies.

Total income reported was nonetheless up 6.5% overall, while the number of physician participants rose 5.4% and the number of CME activities increased by 20.8%.

However, the drop in commercial support suggests that congressional inquiries into industry funding of CME and criticism within academic and medical circles may be having an impact. Tom Sullivan, president of med ed firm Rockpointe Corp., says the reality is probably worse than the data suggest.

“I'm wondering if people are over-reporting,” said Sullivan. “I think there's probably been a drop in support and it's showing up as static because people are being more diligent in how they report.” Some firms, he suggested, may be including advertising and exhibits income, which is not considered commercial support, just to be on the safe side at a time of intense scrutiny on CME funding.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...